Related references
Note: Only part of the references are listed.The landscape of bispecific T cell engager in cancer treatment
Shujie Zhou et al.
BIOMARKER RESEARCH (2021)
Considerations for the Design of Antibody-Based Therapeutics
Dennis R. Goulet et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
T cell-engaging therapies - BiTEs and beyond
Maria-Elisabeth Goebeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy
Hang-Ping Yao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Development of therapeutic antibodies for the treatment of diseases
Ruei-Min Lu et al.
JOURNAL OF BIOMEDICAL SCIENCE (2020)
Predicting Antibody Developability Profiles Through Early Stage Discovery Screening
Marc Bailly et al.
MABS (2020)
Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase
Xin Yu Koh et al.
ONCOGENE (2019)
Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy
Xiang-Min Tong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency
Linlin Wang et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Antibody Structure and Function: The Basis for Engineering Therapeutics
Mark L. Chiu et al.
ANTIBODIES (2019)
89Zr-ImmunoPET companion diagnostics and their impact in clinical drug development
Brooke N. McKnight et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2018)
Preclinical Efficacy of Anti-RON Antibody Drug-Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase
Hang-Ping Yao et al.
MOLECULAR PHARMACEUTICS (2018)
Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth
Huseyin Atakan Ekiz et al.
ONCOIMMUNOLOGY (2018)
Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody-Drug Conjugates
Eshita Khera et al.
BIODRUGS (2018)
Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications
Ruisi Fu et al.
CHEMMEDCHEM (2018)
Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors
Patricia M. LoRusso et al.
INVESTIGATIONAL NEW DRUGS (2017)
Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis
Jun-Feng Chen et al.
ONCOLOGY REPORTS (2017)
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute
Ira Mellman et al.
CANCER IMMUNOLOGY RESEARCH (2016)
The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
Christiane R. Maroun et al.
PHARMACOLOGY & THERAPEUTICS (2014)
High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire
Brandon J. DeKosky et al.
NATURE BIOTECHNOLOGY (2013)
MSP-RON signalling in cancer: pathogenesis and therapeutic potential
Hang-Ping Yao et al.
NATURE REVIEWS CANCER (2013)
Recent trends in antibody-based oncologic imaging
Sukhwinder Kaur et al.
CANCER LETTERS (2012)
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
Tomoyuki Igawa et al.
NATURE BIOTECHNOLOGY (2010)
Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine
Maria J. W. D. Vosjan et al.
NATURE PROTOCOLS (2010)
Development trends for human monoclonal antibody therapeutics
Aaron L. Nelson et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Steven M. Paul et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
E. Martinelli et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Current Constructs and Targets in Clinical Development for Antibody-Based Cancer Therapy
P. M. Deckert
CURRENT DRUG TARGETS (2009)
Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells
M-H Wang et al.
JOURNAL OF PATHOLOGY (2007)
Kinetic exclusion assay technology: Characterization of molecular interactions
RJ Darling et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2004)
Share Paper
